null - CPAP Cancer Lawsuit | People's Justice

Preparing your case review…

Written By

People's Justice Legal Research Team

The PE-PUR foam in recalled Philips CPAP devices releases over 200 chemical compounds when it degrades — including known and suspected human carcinogens. These chemicals travel directly from the device into your airway, exposing your upper respiratory tract, lungs, and through systemic absorption, your kidneys, liver, and bladder. The type of cancer linked to your exposure depends on where in your body these carcinogens accumulate and cause cellular damage.

Nasopharyngeal cancer is the most common cancer type among MDL 3014 plaintiffs — the nasopharynx receives the most direct foam chemical exposure during device use. Lung cancer (adenocarcinoma and squamous cell) is the second most prevalent. Kidney and liver cancers result from systemic absorption and metabolic processing of carcinogenic VOCs. Bladder cancer has been reported due to TDI metabolites excreted through the urinary tract. Throat, thyroid, and other head and neck cancers round out the recognized cancer types in this litigation.

FAQ

Frequently Asked Questions

The recall covers CPAP, BiPAP, and mechanical ventilator devices manufactured by Philips Respironics between approximately 2009 and 2021. The most common plaintiff devices are the DreamStation series (DreamStation CPAP, Auto CPAP, BiPAP, DreamStation Go) and the System One series (50 and 60 Series). Other recalled models include the REMstar SE Auto CPAP, Dorma 400/500, and OmniLab Advanced+. If you purchased a Philips CPAP or BiPAP device before June 2021, there is a strong likelihood it is recalled. Check the Philips recall registration website or contact us for a free device verification.

The cancers most strongly linked to Philips CPAP foam exposure — and most frequently cited in MDL 3014 — include nasopharyngeal cancer (the most common), throat and pharyngeal cancers (oropharyngeal, hypopharyngeal), lung cancer (adenocarcinoma and squamous cell), kidney/renal cell carcinoma, liver cancer (hepatocellular carcinoma), bladder cancer, and thyroid cancer. The carcinogenic chemicals released by degraded PE-PUR foam — including toluene diisocyanate, dimethylformamide, and diethylene glycol — have documented links to these cancer types based on their exposure pathway through the respiratory system and systemic absorption.

Settlement values in the Philips CPAP MDL have not been formally announced — no global settlement matrix has been published as of early 2026. However, based on attorney projections and comparable MDL settlements (including the 3M earplug $6 billion settlement), estimates range from $20,000–$75,000 for non-cancer respiratory injuries, $100,000–$300,000 for early-stage cancer, $300,000–$900,000 for advanced cancer, and $1,000,000–$3,000,000+ for wrongful death claims. The value of your specific case depends on your cancer diagnosis, stage, duration of device use, documentation quality, and the outcome of bellwether trials.

Yes. Non-cancer injuries from recalled Philips CPAP devices are viable personal injury claims. If you experienced documented health effects — including chronic headaches, sinusitis, respiratory inflammation, eye and throat irritation, nausea, chemical sensitivity, or worsening of existing COPD or asthma — during or after using a recalled device, you may have a claim. While non-cancer cases typically settle for less than cancer cases ($20,000–$75,000 range based on projections), they are still actionable and worth evaluating with an attorney.

Filing deadlines depend on your state's statute of limitations for personal injury claims, which range from 2 to 4 years. Critically, in CPAP cancer cases the 'discovery rule' typically starts the clock when you knew — or reasonably should have known — that your cancer was linked to your CPAP device, not necessarily the June 2021 recall date. However, windows are actively closing, particularly in 2-year SoL states for plaintiffs diagnosed in 2022–2023. Filing a Short Form Complaint (SFC) in MDL 3014 protects your claim within the MDL. Contact an attorney immediately — waiting can permanently bar your claim.

MDL 3014 (In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation) is a federal multidistrict litigation case consolidating over 100,000 Philips CPAP personal injury lawsuits before Chief Judge Joy Flowers Conti in the Western District of Pennsylvania in Pittsburgh. Joining the MDL by filing a Short Form Complaint is the primary legal vehicle for cancer and injury claims. You do not have to go to trial individually — the MDL process handles shared pretrial work (discovery, expert battles, bellwether trials) and typically produces a global settlement that all plaintiffs participate in. Your attorney files on your behalf.

Yes. Internal Philips Respironics documents indicate the company received complaints about PE-PUR foam degradation as early as 2015. Philips took no corrective action for approximately six years while continuing to sell the affected devices. This six-year gap between awareness and recall is a cornerstone of the negligence and fraudulent concealment claims in MDL 3014, and it strengthens plaintiffs' cases by supporting punitive damages claims in states that allow them.

Using an ozone-based CPAP cleaner (such as SoClean) significantly accelerates PE-PUR foam degradation and increases the volume of carcinogenic VOCs released — which actually strengthens your exposure claim, as it documents a higher level of chemical exposure. Some plaintiffs have also pursued separate claims against ozone cleaner manufacturers. Ozone cleaning is considered an aggravating exposure factor and is relevant to settlement value. Tell your attorney if you used an ozone cleaner and for how long.

The most important evidence includes: (1) proof of device purchase or use — receipts, prescription records, insurance records for CPAP supplies; (2) the device itself if you still have it, or the model/serial number; (3) medical records documenting your cancer diagnosis, including pathology reports, imaging, and oncology notes; (4) documentation of device use duration relative to diagnosis date; (5) records of any ozone cleaner use; and (6) Philips recall registration confirmation if you registered. Your attorney can help obtain records you don't have — do not delay contacting us because you are missing some documents.

As of early 2026, Philips has NOT announced a global settlement in MDL 3014. Philips has reserved approximately $1.1 billion for litigation, but market analysts estimate its total exposure at $4–6 billion if bellwether trials go unfavorably. Confidential individual settlements have occurred but are not publicly disclosed. The MDL is moving toward a 2026 bellwether trial schedule, which typically creates the conditions for a global settlement. The 3M earplug MDL — a comparable mass tort — resolved for approximately $6 billion after adverse bellwether results.

Yes. Participating in the Philips device replacement program does not release your personal injury or cancer claims. The replacement program addressed the device defect going forward but did not compensate you for any health harm you may have suffered from prior exposure. If you developed cancer or experienced significant health effects while using the recalled device, your legal claim remains intact regardless of whether Philips sent you a replacement unit.

Mass tort litigation in an MDL of this scale typically takes several years from filing to settlement. MDL 3014 was formed in October 2021 and is targeting bellwether trials in 2026 — placing a potential global settlement resolution in the 2026–2028 timeframe based on comparable MDL timelines. Individual plaintiffs receive their settlement funds after a global resolution is reached and claims are allocated through a settlement matrix. While this may feel slow, joining the MDL now protects your claim and positions you to participate in any settlement. Cases filed later may receive less favorable allocations.

CPAP Cancer Lawsuit

The 2021 Philips CPAP recall — one of the largest in medical device history — exposed millions of users to carcinogenic foam particles and VOCs. Cancers linked to exposure include nasopharyngeal, lung, kidney, liver, and bladder cancer. MDL 3014 in Pittsburgh is advancing toward bellwether trials in 2026.

View full case overview

Related Pages

CPAP Cancer Lawsuit